SynthesisPharmacoEconomics2009
Cost of illness of glaucoma: a critical and systematic review.
Synthesis in PharmacoEconomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS).BMJ (Clinical research ed.) · 2021Trial
- Proportion of Fast Progressors in the Central versus Global Visual Field Across Varying Glaucoma Severity Groups.American journal of ophthalmology · 2026Article
- Rapid Campimetry in glaucoma - correspondence with standard perimetry and OCT.Scientific reports · 2024Article
- Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model.The British journal of ophthalmology · 2024Article
- Survival of Visual Function in Patients with Advanced Glaucoma after Standard Guarded Trabeculectomy with MMC.Journal of clinical medicine · 2023Article
- Postoperative Pain after Different Transscleral Laser Cyclophotocoagulation Procedures.International journal of environmental research and public health · 2023Article
- Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma.The British journal of ophthalmology · 2022Article
- Glaucoma Suspects: The Impact of Risk Factor-Driven Review Periods on Clinical Load, Diagnoses, and Healthcare Costs.Translational vision science & technology · 2022Article
- Observational
- Structural Change Can Be Detected in Advanced-Glaucoma Eyes.Investigative ophthalmology & visual science · 2016Article
- Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population.Clinical ophthalmology (Auckland, N.Z.) · 2016Article
- Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2013Article
- Cost-of-illness studies: a guide to critical evaluation.PharmacoEconomics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cost-of-illness studies determine the total financial burden of a disease by considering direct and indirect costs, including medication, diagnostics and surgery. Studies of resource use and costs associated with primary open-angle glaucoma have used varying methodologies. Most have focused on consumption of healthcare resources at various stages of disease to anticipate costs. The direct costs associated with the disease often continue to increase as glaucoma progresses from the earliest to most advanced stages. Determinations of the costs associated with glaucoma progression and prevention should also incorporate the chance of patient non-compliance with treatment. Since glaucoma severity most often correlates with increased costs, minimizing or halting visual field loss and increasing patient treatment compliance may all contribute to a reduction in the overall economic burden of glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.